LXRX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
LXRX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-06-12), Lexicon Pharmaceuticals's current share price is $1.91. Lexicon Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $1.06. Lexicon Pharmaceuticals's Cyclically Adjusted PS Ratio for today is 1.80.
The historical rank and industry rank for Lexicon Pharmaceuticals's Cyclically Adjusted PS Ratio or its related term are showing as below:
During the past years, Lexicon Pharmaceuticals's highest Cyclically Adjusted PS Ratio was 24.07. The lowest was 0.96. And the median was 5.10.
LXRX's Cyclically Adjusted PS Ratio is ranked better thanThe Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Lexicon Pharmaceuticals's adjusted revenue per share data for the three months ended in Mar. 2024 was $0.005. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $1.06 for the trailing ten years ended in Mar. 2024.
The historical data trend for Lexicon Pharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lexicon Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Cyclically Adjusted PS Ratio | Get a 7-Day Free Trial | - | 2.20 | 1.04 | 1.46 | 2.26 |
For the Biotechnology subindustry, Lexicon Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Lexicon Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Lexicon Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Lexicon Pharmaceuticals's Cyclically Adjusted PS Ratio for today is calculated as
Cyclically Adjusted PS Ratio | = | Share Price | / | Cyclically Adjusted Revenue per Share |
= | 1.91 | / | 1.06 | |
= | 1.80 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lexicon Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:
For example, Lexicon Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:
Adj_RevenuePerShare | = | Revenue per Share | / | CPI of Mar. 2024 (Change) | * | Current CPI (Mar. 2024) |
= | 0.005 | / | 131.7762 | * | 131.7762 | |
= | 0.005 |
Current CPI (Mar. 2024) = 131.7762.
Lexicon Pharmaceuticals Quarterly Data
Revenue per Share | CPI | Adj_RevenuePerShare | |
201406 | 0.009 | 100.560 | 0.012 |
201409 | 0.006 | 100.428 | 0.008 |
201412 | 0.253 | 99.070 | 0.337 |
201503 | 0.017 | 99.621 | 0.022 |
201506 | 0.004 | 100.684 | 0.005 |
201509 | 0.005 | 100.392 | 0.007 |
201512 | 1.228 | 99.792 | 1.622 |
201603 | 0.121 | 100.470 | 0.159 |
201606 | 0.193 | 101.688 | 0.250 |
201609 | 0.267 | 101.861 | 0.345 |
201612 | 0.182 | 101.863 | 0.235 |
201703 | 0.175 | 102.862 | 0.224 |
201706 | 0.114 | 103.349 | 0.145 |
201709 | 0.255 | 104.136 | 0.323 |
201712 | 0.326 | 104.011 | 0.413 |
201803 | 0.240 | 105.290 | 0.300 |
201806 | 0.130 | 106.317 | 0.161 |
201809 | 0.066 | 106.507 | 0.082 |
201812 | 0.161 | 105.998 | 0.200 |
201903 | 0.087 | 107.251 | 0.107 |
201906 | 0.091 | 108.070 | 0.111 |
201909 | 2.524 | 108.329 | 3.070 |
201912 | 0.075 | 108.420 | 0.091 |
202003 | 0.075 | 108.902 | 0.091 |
202006 | 0.086 | 108.767 | 0.104 |
202009 | 0.056 | 109.815 | 0.067 |
202012 | 0.002 | 109.897 | 0.002 |
202103 | 0.000 | 111.754 | 0.000 |
202106 | 0.002 | 114.631 | 0.002 |
202109 | 0.000 | 115.734 | 0.000 |
202112 | 0.000 | 117.630 | 0.000 |
202203 | 0.000 | 121.301 | 0.000 |
202206 | 0.000 | 125.017 | 0.000 |
202209 | 0.000 | 125.227 | 0.000 |
202212 | 0.000 | 125.222 | 0.000 |
202303 | 0.000 | 127.348 | 0.000 |
202306 | 0.002 | 128.729 | 0.002 |
202309 | 0.001 | 129.860 | 0.001 |
202312 | 0.003 | 129.419 | 0.003 |
202403 | 0.005 | 131.776 | 0.005 |
Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Thank you for viewing the detailed overview of Lexicon Pharmaceuticals's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Philippe Amouyal | director | C/O CAVA GROUP, INC., 14 RIDGE SQUARE NW, SUITE 500, WASHINGTON DC 20016 |
Lonnel Coats | director, officer: President and CEO | 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381 |
Raymond Debbane | director, 10 percent owner | C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, NEW YORK NY 10022 |
Thomas Garner | officer: SVP, Chief Commercial Officer | 2445 TECHNOLOGY FOREST BLVD, 11TH FLOOR, SPRING TX 77381 |
Jeffrey L Wade | officer: EVP, Gen. Counsel | 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381 |
Wendy Mcdermott | officer: VP, Human Resources | 2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS TX 77381 |
Diane E. Sullivan | director | C/O AMARIN CORPORATION PLC, 77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2 L2 D02 VK60 |
Artal International S.c.a. | director, 10 percent owner | VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661 |
Invus Partners, Llc | director, 10 percent owner | 750 LEXINGTON AVE, 30TH FL, NEW YORK NY 10022 |
Ulys, Llc | director, 10 percent owner | C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, 30TH FLOOR, NEW YORK NY 10022 |
Kiernan Seth | officer: VP, Chief Commercial Officer | 2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS TX 77381 |
Kenneth B. Kassler-taub | officer: SVP, Regulatory & QA | 2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS TX 77381 |
Kristen Alexander | officer: VP, Finance and Accounting | 2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS TX 77381 |
Craig B Granowitz | officer: SVP, Chief Medical Officer | 58 CHESTNUT STREET, UNIT #3, MORRISTOWN NJ 07960 |
James F Tessmer | officer: VP, Finance & Acctg | 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381 |
From GuruFocus
By Marketwired • 08-21-2023
By GlobeNewswire • 11-12-2023
By sperokesalga sperokesalga • 05-31-2023
By Marketwired • 10-09-2023
By Marketwired • 09-07-2023
By sperokesalga sperokesalga • 05-10-2023
By Marketwired • 11-03-2023
By sperokesalga sperokesalga • 06-01-2023
By Marketwired • 07-28-2023
By GlobeNewswire GlobeNewswire • 06-15-2023